TABLE 2.
Clinical data on DEB-TACE.
| Variables | Data |
|---|---|
| Inpatient duration, months | 9.0 (7.0, 12.0) |
| Hospitalization cost, ×104 ¥ | 6.7 ± 2.0 |
| DEB-TACE sessions | 1.7 ± 0.9 |
| Additional embolization | |
| Gelatin sponge particles | 5 (17.2%) |
| Embolization microspheres | 6 (20.7%) |
| Polyvinyl alcohol particles | 4 (13.8%) |
| Complications, n (%) | 21 (72.4%) |
| Fever | 3 (10.3%) |
| Nausea | 5 (17.2%) |
| Vomiting | 3 (10.3%) |
| Thrombocytopenia | 3 (10.3%) |
| hyperbilirubinemia | 5 (17.2%) |
| Leukopenia | 2 (6.9%) |
| Abdominal pain | 12 (41.4%) |
| Raised ALT/AST | 8 (27.6%) |
| Other interventional treatments, n (%) | 13 (44.8%) |
| Conventional TACE | 8 (31.0%) |
| PTCD | 3 (10.3%) |
| 125I seed implantation | 1 (3.4%) |
| Thermal ablation | 3 (10.3%) |
| Drainage of liver abscess | 1 (3.4%) |
ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; TACE = Transcatheter arterial chemoembolization; PTCD = Percutaneous transhepatic cholangial drainage.